Cite
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
MLA
Venkatakrishnan, Karthik, et al. “Phase 1 Study of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in East Asian Cancer Patients: Pharmacokinetics and Recommended Phase 2 Dose.” Investigational New Drugs, vol. 33, no. 4, Aug. 2015, pp. 942–53. EBSCOhost, https://doi.org/10.1007/s10637-015-0258-y.
APA
Venkatakrishnan, K., Kim, T. M., Lin, C.-C., Thye, L. S., Chng, W. J., Ma, B., Chen, M. H., Zhou, X., Liu, H., Kelly, V., & Kim, W. S. (2015). Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. Investigational New Drugs, 33(4), 942–953. https://doi.org/10.1007/s10637-015-0258-y
Chicago
Venkatakrishnan, Karthik, Tae Min Kim, Chia-Chi Lin, Lim Soon Thye, Wee Joo Chng, Brigette Ma, Ming Huang Chen, et al. 2015. “Phase 1 Study of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in East Asian Cancer Patients: Pharmacokinetics and Recommended Phase 2 Dose.” Investigational New Drugs 33 (4): 942–53. doi:10.1007/s10637-015-0258-y.